Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, when combined with lifestyle interventions, produces clinically significant weight loss (average 14.9-16.0% body weight reduction) in adults with obesity or overweight with comorbidities, significantly outperforming placebo and daily liraglutide 3.0 mg.
If you have obesity or are overweight with a related health issue, once-weekly semaglutide 2.4 mg is a highly effective tool for weight loss when combined with diet and exercise. It works by mimicking a hormone that slows digestion and reduces appetite. You start with a low dose to minimize stomach upset, then increase it weekly until you reach the full dose. Expect significant weight loss (around 15%) over 6-8 months, which is much more than diet and exercise alone. Be aware of potential side effects like nausea, which usually fade, and avoid the medication if you have a specific family history of thyroid cancer.
Across all published trials, semaglutide demonstrated a statistically significant greater percent decrease in weight from baseline and a greater likelihood of patients losing ≥5% of their body weight when compared with either placebo or liraglutide.
Why this rating
Based on multiple large-scale, randomized, placebo-controlled phase 3 trials (STEP program) with consistent results.
Source
Once-Weekly Semaglutide for Weight Management: A Clinical Review
Abby Fornes et al. · Journal of Pharmacy Technology · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →